Accessibility Menu
Celularity logo

Celularity(NASDAQ) CELU

Current Price$0.75
Market Cap$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-99%
1 Year-79%
1 Month+9%
Celularity last closing stock price
MetricPriceDate
Last closeUSD 0.762026-07-23
Celularity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.05%USD 0.772026-07-16
1 month+8.6%USD 0.702026-06-23
3 month-31.53%USD 1.112026-04-24
Year to date-31.53%USD 1.112025-12-31
1 year-78.83%USD 3.592025-07-23
3 year-85.19%USD 5.132023-07-24
5 year-99.22%USD 97.502021-07-23
Since inception-99.2%USD 98.002019-08-08

Celularity Financials at a Glance

Market Cap

$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$26.55M

Net Income (TTM)

-$91.71M

EPS (TTM)

-$3.58

P/E Ratio

-0.21

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Price

$0.75

Volume

0

Open

$0.75

Previous Close

$0.75

Daily Range

$0.75 - $0.75

52-Week Range

$0.56 - $4.31

Estimated Earnings Date

Aug 12, 2026

CELU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celularity

Celularity develops cell-based therapies and biomaterials from placental tissue. Its products help treat cancer, immune, and wound care needs. Hospitals and patients use these solutions for advanced treatment and recovery options.

Products and Services

  • Degenerative Disease: Wound care and surgical biomaterials for hospitals and clinics.
  • BioBanking: Collection and storage of stem cells from umbilical cords and placentas for individuals.
  • Cell Therapy: Early-stage therapies for cancer and immune diseases, using placental cells.
  • Contract Manufacturing: Production services for other cell therapy companies.
  • Licensing and Royalties: Intellectual property licensed to partners in dental and medical fields.

Growth and Expansion

  • Acquired Rebound product and assets from Sequence LifeScience in October 2024.
  • Expanded biomaterials portfolio with new products planned for 2025–2027.
  • Formed research collaboration with Regeneron (ended August 2025).
  • Signed licensing agreement with BioCellgraft for dental market in December 2023.

What Makes Celularity Stand Out

Celularity uses a proprietary platform to produce therapies from placental tissue, offering scalable manufacturing. The company operates across cell therapy, biomaterials, and biobanking, creating a diversified business model. In-house manufacturing and a large patent portfolio support its competitive position.

Five Things You Need to Know

  • Q2 2025 revenue was $6 million, down 52.6% from Q2 2024.
  • Q2 2025 net loss was $24.5 million, compared to $6.5 million in Q2 2024.
  • Cash and cash equivalents were $0.9 million as of June 30, 2025.
  • Outstanding debt totaled $43.4 million as of June 30, 2025.

Bottom Line

Celularity has evolved through acquisitions, product expansion, and diversification across three business segments. The company faces financial challenges but maintains a broad portfolio in cell therapy and biomaterials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

115

CEO

Robert Joseph Hariri Gordon, MD, PhD

Website

www.celularity.com

Headquarters

Florham Park, NJ 07932, US

CELU Financials

Key Financial Metrics (TTM)

Gross Margin

76.04%

Operating Margin

-230.92%

Net Income Margin

-345.44%

Return on Equity

411.46%

Return on Capital

-2159.49%

Return on Assets

-85.45%

Earnings Yield

-4.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

28.95M

Volume

0

Avg. Volume

155.18K

Financials (TTM)

Gross Profit

$20.19M

Operating Income

-$61.31M

EBITDA

-$77.62M

Operating Cash Flow

-$13.25M

Capital Expenditure

-$1.00

Free Cash Flow

-$13.25M

Cash & ST Invst.

$6.18M

Total Debt

$40.90M

Celularity Performance Analysis

Celularity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 17,975,000-15.7%
20232023-12-31USD 22,771,00026.7%
20242024-12-31USD 54,220,000138.1%
20252025-12-31USD 26,550,000-51.0%
Celularity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-37.0%
Q22025-06-30-49.8%
Q32025-09-30-7.9%
Q42025-12-31-22.3%
Celularity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.95N/A
20232023-12-31USD -11.02N/A
20242024-12-31USD -2.64-76.0%
20252025-12-31USD -3.5935.6%
Celularity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-41.2%
Q22025-06-30-21.6%
Q32025-09-3013.8%
Q42025-12-31-8.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$4.10M

-77.4%

Gross Profit

$8.56M

-20.7%

Gross Margin

2.08%

N/A

Market Cap

$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$191.30K

N/A

Employees

115

N/A

Net Income

-$24.36M

-83.3%

EBITDA

-$21.66M

-185.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$6.18M

+736.7%

Total Debt

$40.90M

-40.6%

Accounts Receivable

$4.65M

-65.7%

Inventory

$571.00K

-89.4%

Long Term Debt

$26.90M

-56.9%

Short Term Debt

$14.00M

+120.1%

Return on Assets

-85.45%

N/A

Return on Invested Capital

-2.31%

N/A

Free Cash Flow

-$5.10M

-431.8%

Operating Cash Flow

-$5.10M

-420.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BTAIBioXcel Therapeutics, Inc.
$0.85-2.34%
ANVSAnnovis Bio, Inc.
$1.66-5.14%
GBIOGeneration Bio Co.
$5.34+0.00%
FGENFibroGen, Inc.
$9.07-1.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.30-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.16+0.02%
CLFCleveland-Cliffs
$11.05+0.01%

Questions About CELU

What is the current price of Celularity?

Celularity is trading at $0.75 per share.

What is the 52-week range for Celularity?

Over the past 52 weeks, Celularity has traded between $0.56 and $4.31.

How much debt does Celularity have?

As of the most recent reporting period, Celularity reported total debt of $74.71M.

How much cash does Celularity have on hand?

Celularity reported $6.18M in cash and cash equivalents in its most recent financial results.

What is Celularity’s dividend yield?

Celularity does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services